Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

• Main Authors: Paul Baverel (Author), Lorin Roskos (Author), Manasa Tatipalli (Author), Nancy Lee (Author), Paul Stockman (Author), Maria Taboada (Author), Paolo Vicini (Author), Kevin Horgan (Author), Rajesh Narwal (Author)
• Format: Book
• Published: Wiley, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meanin...